TOKYO, Oct 4, 2023 - (JCN Newswire) - - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy ...

TOKYO, May 8, 2020 - (JCN Newswire) - - Hitachi, Ltd. (TSE:6501) has announced that Hitachi has provided its advanced proton therapy system to Clinica Universidad de Navarra (Madrid, Spain) and the ...

TOKYO--(BUSINESS WIRE)--Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced that Mayo Clinic in Phoenix, AZ began treating patients with its advanced PROBEAT-V proton therapy system on March 14. The ...

Hitachi, Ltd. has entered into an agreement to provide Centro Nazionale di Adroterapia Oncologica (CNAO) with its proton therapy system. In the comprehensive public tender process, Hitachi has been ...

Hitachi, Ltd. and Hokkaido University announced that it has obtained U.S. Food & Drug Administration (FDA) 510(k) clearance on December 26, 2017 for the commercialization of "Real Time Image Gating ...

Hitachi Ltd and Mitsubishi Electric Corp have signed an agreement to transfer Mitsubishi Electric's particle therapy system business to Hitachi and integrate to one entity. After their negotiation and ...

SINGAPORE, Aug 18, 2016 - (JCN Newswire) - Hitachi Asia Ltd. and Hitachi, Ltd. announced today that Hitachi Asia has received an order for a proton beam therapy system ("PBT" system) from the National ...

As part of a deal by Hitachi Chemical to acquire a 19.9% equity interest in Caladrius Biosciences' ($CLBS) PCT cell therapy and manufacturing subsidiary, the Japanese ...

TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy ...